These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 23944319)

  • 1. Current and future therapies for hepatitis C virus infection.
    Ozaras R; Yemisen M; Balkan İİ
    N Engl J Med; 2013 Aug; 369(7):679. PubMed ID: 23944319
    [No Abstract]   [Full Text] [Related]  

  • 2. Current and future therapies for hepatitis C virus infection.
    Ghany MG; Liang TJ
    N Engl J Med; 2013 Aug; 369(7):679-80. PubMed ID: 23944318
    [No Abstract]   [Full Text] [Related]  

  • 3. Hepatitis C virus infection in Taiwan: Past, present, and future.
    Kao JH
    J Formos Med Assoc; 2016 Feb; 115(2):65-6. PubMed ID: 26228687
    [No Abstract]   [Full Text] [Related]  

  • 4. Hepatitis C virus: prospects for future therapies.
    Wilkinson T
    Curr Opin Investig Drugs; 2001 Nov; 2(11):1516-22. PubMed ID: 11763151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SASLT position statement on the direct-acting antiviral agents for the treatment of hepatitis C virus infection.
    Alghamdi AS; Alqutub A; Abaalkhail F; Sanai FM; Alghamdi H; Altraif I; Alswat KA; Alghamdi MY; Babatin MA; Alfaleh FZ
    Saudi J Gastroenterol; 2015; 21(2):60-3. PubMed ID: 25843190
    [No Abstract]   [Full Text] [Related]  

  • 6. [Should Hepatitis C be treated? Objectives of antiviral treatments in hepatitis C virus infection].
    Degos F
    Gastroenterol Clin Biol; 1997; 21(1 Pt 2):S57-65. PubMed ID: 9161515
    [No Abstract]   [Full Text] [Related]  

  • 7. Practical consequences of hepatitis C virus quasispecies for target-specific antivirals.
    Fanning LJ
    J Infect Dis; 2008 Sep; 198(6):797-9. PubMed ID: 18637751
    [No Abstract]   [Full Text] [Related]  

  • 8. Accurate hepatitis C virus genotyping and selection of optimal therapy: lessons from a St Petersburg strain infection.
    Knops E; Heger E; Koenig C; Moebius U; Lübke N; Kaiser R; Di Cristanziano V; Hüsgen L; Kocyigit C; Rupp J; Sierra S
    Clin Microbiol Infect; 2018 Apr; 24(4):440-441. PubMed ID: 29104172
    [No Abstract]   [Full Text] [Related]  

  • 9. Recommendation for treatment of hepatitis C virus infection.
    Kaymakoğlu S; Köksal İ; Tabak F; Akarca US; Akbulut A; Akyüz F; Bodur H; Çağatay A; Dinçer D; Esen Ş; Güner R; Gürel S; Köse Ş; Şentürk Ö; Şimşek H; Yamazhan T; Yılmaz Y; Idilman R; Guidelines Study Group VH
    Turk J Gastroenterol; 2017 Dec; 28(Suppl 2):94-100. PubMed ID: 29303106
    [No Abstract]   [Full Text] [Related]  

  • 10. Retreatment of a treatment-experienced patient with genotype 6 hepatitis C virus infection: follow-up on a reported case.
    Spooner LM; Abraham GM
    Am J Health Syst Pharm; 2015 Jan; 72(1):14-6. PubMed ID: 25511831
    [No Abstract]   [Full Text] [Related]  

  • 11. New hepatitis C therapies.
    Pawlotsky JM
    Semin Liver Dis; 2014 Feb; 34(1):7-8. PubMed ID: 24782253
    [No Abstract]   [Full Text] [Related]  

  • 12. Novel therapies in Hepatitis C virus. Preface.
    Pockros PJ
    Clin Liver Dis; 2009 Aug; 13(3):xiii. PubMed ID: 19628152
    [No Abstract]   [Full Text] [Related]  

  • 13. Management of hepatitis C virus genotype 4.
    Abdo AA; Lee SS
    J Gastroenterol Hepatol; 2004 Nov; 19(11):1233-9. PubMed ID: 15482528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Standard antiviral therapies against HCV infection].
    Sakamoto N
    Nihon Shokakibyo Gakkai Zasshi; 2016; 113(1):20-4. PubMed ID: 26743549
    [No Abstract]   [Full Text] [Related]  

  • 15. The interferon sensitivity determining region: all hepatitis C virus isolates are not the same.
    Herion D; Hoofnagle JH
    Hepatology; 1997 Mar; 25(3):769-71. PubMed ID: 9049233
    [No Abstract]   [Full Text] [Related]  

  • 16. Hepatitis B and C virus resistance to antiviral therapies--EASL-AASLD-APASL-ALEH-IASL conference.
    Buti M
    IDrugs; 2008 Apr; 11(4):239-41. PubMed ID: 18379952
    [No Abstract]   [Full Text] [Related]  

  • 17. Emerging issues on hepatitis C virus infection after the introduction of the Directly Acting Antivirals.
    Ippolito G; Antonelli G
    Clin Microbiol Infect; 2016 Oct; 22(10):824-825. PubMed ID: 27863749
    [No Abstract]   [Full Text] [Related]  

  • 18. Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1.
    Calcagno A; Boglione L; De Rosa FG; Di Perri G; Bonora S
    Clin Infect Dis; 2013 Jun; 56(11):1677-8. PubMed ID: 23418276
    [No Abstract]   [Full Text] [Related]  

  • 19. [Hepatitis C virus genotype 4: epidemiology and treatment].
    Castera L; Morice Y; Grando V; Bon C; Dény P; Roulot D
    Gastroenterol Clin Biol; 2003 Jun; 27(6-7):596-604. PubMed ID: 12910223
    [No Abstract]   [Full Text] [Related]  

  • 20. Regression of splenic lymphoma after treatment of hepatitis C virus infection.
    Mazzaro C; Little D; Pozzato G
    N Engl J Med; 2002 Dec; 347(26):2168-70; author reply 2168-70. PubMed ID: 12501232
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.